New
Retatrutide 10 mg
109,00 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
Description
Retatrutide
Weight Loss / Metabolism
MECHANISM OF ACTION
Triple agonist: GLP-1R for satiety and insulin secretion; GIPR for glucose-dependent insulin secretion and energy expenditure through activation of brown adipose tissue; and the glucagon receptor for energy expenditure, lipolysis, and normalization of hepatic glucose production. The GIP base conjugated with a fatty acid extends the half-life. Triple-receptor activation provides a superior metabolic effect compared to dual agonists.
KEY BENEFITS
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
SIDE EFFECTS AND SAFETY
Prominent gastrointestinal side effects, such as nausea, vomiting, and diarrhea. Its action on the glucagon receptor leads to increased energy expenditure and possible mild hyperglycemia at the start of treatment. Titration minimizes intolerance.
RESEARCH AND CLINICAL NOTES
Jastreboff et al. (NEJM 2023): 24.2% reduction in body weight at 48 weeks with the highest dose; the highest result to date in a weight-loss drug trial. Phase III TRIUMPH trial ongoing. Compound under development by Eli Lilly.
TARGET PROFILE:
Obesity Medicine, Endocrinology, and Weight Loss.
Additional information
| Weight | ,26 kg |
|---|
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
New
AOD-9604
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
New
CJC-1295 5 mg without DAC + IPA 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Synergistic optimization of endogenous GH secretion.
- Reference GH Peptide Stack for Body Composition.
- Increased lean body mass, fat loss, and recovery.
- Maintenance of the pulsatile rhythm of GH, with lower long-term risk.
- Ipamorelin's selectivity minimizes the increase in cortisol and prolactin.
CJC-1295 without DAC
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Physiological pattern of pulsatile GH secretion.
- Lower risk of desensitization compared to the DAC version.
- Improved body composition and recovery.
- Improved sleep quality, with synergistic effects when taken at night.
- Suitable for use in combination with GHRP-class peptides.
New
DSIP
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sleep quality, especially deep, slow-wave (delta) sleep.
- Stress-reducing and anxiolytic effects.
- Normalization of disrupted sleep patterns.
- Potential application in opioid/alcohol withdrawal syndrome.
- Geroprotector: Anticancer Properties in Animal Models.
Glutathione
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Comprehensive reduction of oxidative stress.
- Improved Phase II hepatic detoxification.
- Supports the immune system.
- Skin lightening through the inhibition of melanin synthesis.
- Neuroprotection in Parkinson's disease and other degenerative conditions.
- Improving Insulin Sensitivity in Metabolic Research.
IGF-1 LR3
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Powerful anabolic effect: muscle hypertrophy and hyperplasia.
- Improved protein synthesis and nitrogen retention.
- Improved glucose utilization and fat oxidation.
- Accelerated injury healing and tissue regeneration.
- Extended half-life that allows for once-daily dosing.
New
PT-141
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sexual desire in men and women.
- Improvement of erectile function via the central nervous system.
- Approved by the FDA for HSDD in premenopausal women as Vyleesi.
- Effective in patients who do not respond to PDE5 inhibitors.
- It can be used as needed, 45–90 minutes before the activity.
New
Semaglutide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
